The Experts below are selected from a list of 195 Experts worldwide ranked by ideXlab platform
Thomas R Kozel - One of the best experts on this subject based on the ideXlab platform.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23 degrees C and 37 degrees C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to
-
human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Charlotte M Bohlman, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to <0.001) and by reduction in number of infection foci and their size in the kidney. In vitro studies found that M1G1 promoted phagocytosis and phagocytic killing of C. albicans yeast cells by mouse peritoneal macrophages and was required for activation of the mouse complement cascade. Thus, human antimannan Antibody may have a protective role in host resistance to systemic candidiasis.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice.
Infection and Immunity, 2005Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to
Mason X. Zhang - One of the best experts on this subject based on the ideXlab platform.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23 degrees C and 37 degrees C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to
-
human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Charlotte M Bohlman, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to <0.001) and by reduction in number of infection foci and their size in the kidney. In vitro studies found that M1G1 promoted phagocytosis and phagocytic killing of C. albicans yeast cells by mouse peritoneal macrophages and was required for activation of the mouse complement cascade. Thus, human antimannan Antibody may have a protective role in host resistance to systemic candidiasis.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice.
Infection and Immunity, 2005Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to
Robert H Purcell - One of the best experts on this subject based on the ideXlab platform.
-
chimpanzee fab fragments and a derived humanized Immunoglobulin G1 Antibody that efficiently cross neutralize dengue type 1 and type 2 viruses
Journal of Virology, 2004Co-Authors: Ana P Goncalvez, Claire Wernly, Robert H PurcellAbstract:Passive immunization with monoclonal antibodies from humans or nonhuman primates represents an attractive alternative to vaccines for prevention of illness caused by dengue viruses (DENV) and other flaviviruses, including the West Nile virus. In a previous study, repertoire cloning to recover Fab fragments from bone marrow mRNA of chimpanzees infected with all four DENV serotypes (dengue virus serotype 1 [DENV-1] to DENV-4) was described. In that study, a humanized Immunoglobulin G1 (IgG1) Antibody that efficiently neutralized DENV-4 was recovered and characterized. In this study, the phage library constructed from the chimpanzees was used to recover Fab antibodies against the other three DENV serotypes. Serotype-specific neutralizing Fabs were not identified. Instead, we recovered DENV-neutralizing Fabs that specifically precipitated the envelope protein and were cross-reactive with all four DENV serotypes. Three of the Fabs competed with each other for binding to DENV-1 and DENV-2, although each of these Fabs contained a distinct complementarity determining region 3 (CDR3)-H sequence. Fabs that shared an identical or nearly identical CDR3-H sequences cross-neutralized DENV-1 and DENV-2 at a similar high 50% plaque reduction neutralization test (PRNT50) titer, ranging from 0.26 to 1.33 μg/ml, and neutralized DENV-3 and DENV-4 but at a titer 10- to 20-fold lower. One of these Fabs, 1A5, also neutralized the West Nile virus most efficiently among other flaviviruses tested. Fab 1A5 was converted to a full-length Antibody in combination with human sequences for production in mammalian CHO cells. Humanized IgG1 1A5 proved to be as efficient as Fab 1A5 for cross-neutralization of DENV-1 and DENV-2 at a titer of 0.48 and 0.95 μg/ml, respectively. IgG1 1A5 also neutralized DENV-3, DENV-4, and the West Nile virus at a PRNT50 titer of approximately 3.2 to 4.2 μg/ml. This humanized Antibody represents an attractive candidate for further development of immunoprophylaxis against DENV and perhaps other flavivirus-associated diseases.
-
identification of chimpanzee fab fragments by repertoire cloning and production of a full length humanized Immunoglobulin G1 Antibody that is highly efficient for neutralization of dengue type 4 virus
Journal of Virology, 2004Co-Authors: Tetsu Yamashiro, Ana P Goncalvez, Claire Wernly, Darren Schofield, Suzanne U Emerson, Robert H PurcellAbstract:A safe and effective dengue vaccine is still not available. Passive immunization with monoclonal antibodies from humans or nonhuman primates represents an attractive alternative for the prevention of dengue virus infection. Fab monoclonal antibodies to dengue type 4 virus (DENV-4) were recovered by repertoire cloning of bone marrow mRNAs from an immune chimpanzee and analyzed for antigen binding specificity, V H and V L sequences, and neutralizing activity against DENV-4 in vitro. Fabs 5A7, 3C1, 3E4, and 7G4 were isolated from a library constructed from a chimpanzee following intrahepatic transfection with infectious DENV-4 RNA. Fabs 5H2 and 5D9, which had nearly identical V H sequences but varied in their V L sequences, were recovered from a library constructed from the same chimpanzee after superinfection with a mixture of DENV-1, DENV-2, and DENV-3. In radioimmunoprecipitation, Fab 5A7 precipitated only DENV-4 prM, and Fabs 3E4, 7G4, 5D9, and 5H2 precipitated DENV-4 E but little or no prM. Fab 3E4 and Fab 7G4 competed with each other for binding to DENV-4 in an enzyme-linked immunosorbent assay, as did Fab 3C1 and Fab 5A7. Fab 5H2 recognized an epitope on DENV-4 that was separate from the epitope(s) recognized by other Fabs. Both Fab 5H2 and Fab 5D9 neutralized DENV-4 efficiently with a titer of 0.24 to 0.58 μg/ml by plaque reduction neutralization test (PRNT), whereas DENV-4-neutralizing activity of other Fabs was low or not detected. Fab 5H2 was converted to full-length Immunoglobulin G1 (IgG1) by combining it with human sequences. The humanized chimpanzee Antibody IgG1 5H2 produced in CHO cells neutralized DENV-4 strains from different geographical origins at a similar 50% plaque reduction (PRNT 50 ) titer of 0.03 to 0.05 μg/ml. The DENV-4 binding affinities were 0.42 nM for Fab 5H2 and 0.24 nM for full-length IgG1 5H2. Monoclonal Antibody IgG1 5H2 may prove valuable for passive immunoprophylaxis against dengue virus in humans.
Kosaku Nitta - One of the best experts on this subject based on the ideXlab platform.
-
Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
Contributions To Nephrology, 2018Co-Authors: Yuko Iwabuchi, Takashi Takei, Takahito Moriyama, Mitsuyo Itabashi, Kosaku NittaAbstract:: Minimal change nephrotic syndrome (MCNS) usually responds to steroids but frequently relapses, requiring additional treatment with immunosuppressive agents. Rituximab is a chimeric murine/human monoclonal Immunoglobulin G1 Antibody that targets CD20, a B-cell differentiation marker. B-cell recovery begins at approximately 6 months following the completion of treatment. Rituximab has a beneficial effect, with the sustained remission or reduction of proteinuria in patients with steroid-dependent MCNS. Relapses are thought to be associated with an increase in CD19 cells. The mean serum half-life of rituximab was reported to be 10-15 days in patients with steroid-dependent MCNS. Only infusion reactions, such as rash and chills, occurred after single-dose rituximab infusion and can be managed by pre-medication or infusion rate adjustments. Even though severe adverse effects of rituximab are not expected, we must be aware of potentially life-threatening adverse effects. Controlled randomized trials that include adult patients with steroid-dependent MCNS are required to prove the efficacy and safety of rituximab and to evaluate the cost-effectiveness of rituximab treatment. In this review, we highlight recent studies and discuss the effects of these studies on the management of patients with MCNS in adults.
-
Rituximab and minimal change nephrotic syndrome: a therapeutic option
Clinical and Experimental Nephrology, 2011Co-Authors: Takashi Takei, Kosaku NittaAbstract:Minimal change nephrotic syndrome (MCNS) usually responds to steroids but frequently relapses, requiring additional treatment with immunosuppressive agents. Rituximab is a chimeric murine/human monoclonal Immunoglobulin G1 Antibody that targets CD20, a B-cell differentiation marker. B-cell recovery begins at approximately 6 months following the completion of treatment. Rituximab has a beneficial effect, with the sustained remission or reduction of proteinuria in patients with steroid-dependent MCNS. Relapses are thought to be associated with an increase in CD19 cells. The mean serum half-life of rituximab was reported to be 10–15 days in patients with steroid-dependent nephrotic syndrome. Only infusion reactions, such as rash and chills, occurred after single-dose rituximab infusion and can be managed by pre-medication or infusion rate adjustments. Even though severe adverse effects of rituximab are not expected, physicians must be aware of potentially life-threatening adverse effects. Controlled randomized trials that include adult patients with steroid-dependent or steroid-resistant MCNS are required to prove the efficacy and safety of rituximab and to evaluate the cost-effectiveness of rituximab treatment.
Paul W H I Parren - One of the best experts on this subject based on the ideXlab platform.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23 degrees C and 37 degrees C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to
-
human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice
Infection and Immunity, 2006Co-Authors: Mason X. Zhang, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Charlotte M Bohlman, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to <0.001) and by reduction in number of infection foci and their size in the kidney. In vitro studies found that M1G1 promoted phagocytosis and phagocytic killing of C. albicans yeast cells by mouse peritoneal macrophages and was required for activation of the mouse complement cascade. Thus, human antimannan Antibody may have a protective role in host resistance to systemic candidiasis.
-
Human recombinant antimannan Immunoglobulin G1 Antibody confers resistance to hematogenously disseminated candidiasis in mice.
Infection and Immunity, 2005Co-Authors: Mason X. Zhang, M. Charlotte Bohlman, Carol Itatani, S C St Jeor, Paul W H I Parren, Dennis R Burton, Thomas R KozelAbstract:Mannan is a major cell wall component found in Candida species. Natural antimannan Antibody is present in sera from most normal adults, but its role in host resistance to hematogenously disseminated candidiasis is unknown. The purpose of this study was to develop recombinant human antimannan Antibody and to study its protective function. A phage Fab display combinatorial library containing Fab genes from bone marrow lymphocytes was screened with Candida albicans yeast cells and chemically purified mannan. One antimannan Fab, termed M1, was converted to a full-length Immunoglobulin G1 Antibody, M1G1, and M1G1 was produced in CHO cells. The M1G1 epitope was found in C. albicans serotypes A and B, Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis. Its expression was active at both 23°C and 37°C and uniform over the cell surface. BALB/c mice passively immunized with M1G1 were more resistant than control mice to a lethal hematogenous infection by C. albicans, as evidenced by extension of survival in an M1G1 dose-dependent manner (P, 0.08 to